ResMed Inc.

RMD Healthcare Medical Instruments & Supplies

ResMed Inc.’s revenue for fiscal 2026 (year ended June 2026) was $5.7 billion, up 9.85% from fiscal 2025. In the quarter to June 2026, revenue grew 8.58%, EPS grew 2.32%, free cash flow fell 21.3% and total debt fell 39.3%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years, revenue growth for ten, operating cash flow growth for three.

238.97 3.26 −1.35%
Market cap
$34.1B
P/E
22.8×
Fwd P/E
16.6×
Dividend yield
1.03%
F-score
6/9
Altman Z
10.00
Beneish M
−2.59
Dividend safety
96/100
Older periods Sep '25 Dec '25 Mar '26 Jun '26
ROE

+8 more TTM periods

25.41% 25.68% 25.25% 24.27%
Piotroski F-Score
7 7 7 6
ROA
18.52% 19.00% 18.59% 17.77%
ROIC
21.19% 21.42% 22.59% 21.38%
Return on Tangible Assets
49.01% 47.40% 46.33% 43.38%
Average Days of Receivables
62.99 66.64 65.83 66.90
Free Cash Flow per Share
12.02 12.18 11.95 11.19
Free Cash Flow
1,756.56 1,776.59 1,736.26 1,628.66
Capital Expenditures
(126.81) (137.90) (153.70) (177.17)
Other line items
Cash ROIC
22.20% 21.82% 20.29% 19.26%
Accounts Receivable Turnover
6.12 5.85 5.81 5.72
Accounts Payable Turnover
8.13 8.97 8.58 7.50
Inventory Turnover
2.25 2.34 2.40 2.35
Average Days of Payables
46.39 43.27 46.89 51.21
Days of Inventory on Hand
164.48 159.34 156.47 156.80
Tax Rate
(0.17) (0.18) (0.20) (0.21)
Research and Development Expense of Revenue
6.45% 6.46% 6.48% 6.69%
Selling, General and Administrative Expense of Revenue
19.27% 19.45% 19.69% 19.80%
Share Based Compensation of Revenue
1.76% 1.83% 1.84% 1.85%
Interest Coverage
(119.75) (78.10) (54.41) (37.80)
Operating CF/Net income
1.31 1.29 1.24 1.19
Depreciation/Fixed assets
0.43 0.44 0.46 0.42
Capex/Depreciation
(0.53) (0.56) (0.58) (0.73)
Revenue per Share
35.96 37.01 38.10 38.85
Operating CF per Share
12.88 13.13 13.00 12.41
Capex per Share
(0.87) (0.95) (1.06) (1.22)
Capex to Sales
0.02 0.03 0.03 0.03

Fold the line items

Columns are period end dates